Advertisement

HIV Special Issue - Guest Editors

Prof Linda-Gail Bekker

Guest Editor, PLOS Medicine Advances in HIV Prevention, Treatment and Cure

Linda-Gail Bekker is Deputy Director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, UCT and Chief Operating Officer of the Desmond Tutu HIV Foundation. She is a physician scientist and infectious disease specialist. Her research interests include programmatic and action research around antiretroviral roll out and TB integration, prevention of HIV in women, youth and men who have sex with men.

She is PI of the NIH (USA) funded UCTCTU and remains actively involved in the work of the 4 associated clinical research sites and 4 DAIDS networks. In particular she has chaired protocols for the HVTN and HPTN and has been IoR in a number of network related protocols. She has served on numerous international and local scientific and working committees. She has developed a keen interest more recently on primary prevention in key populations, adolescents and young women. Leading a lrage team of more than 300 staff, she has a number of investigator driven projects and programs that seek to find scalable solutions to some of Africa’s most pressing health challenges.  She has also now taken up her Presidency of the International AIDS Society and serves as the International Co-Chair of the 9th IAS Conference on HIV Science in Paris in July 2017 and the International AIDS Conference in Amsterdam in 2018.

Competing Interests: Prof Bekker is employed by the Desmond Tutu HIV Centre, UCT and the Desmond Tutu HIV Foundation. She has received honoraria for technical inputs from Jansen and Merck in the last 5 years and her organisation has benefited from grants from Gilead, Merck and ViiV. 


Dr. Steven G. Deeks

Guest Editor, PLOS Medicine Advances in HIV Prevention, Treatment and Cure

Steven G. Deeks is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital.  Dr. Deeks has been engaged in HIV research and clinical care since 1993.  He is a recognized expert on HIV-associated immune dysfunction and its impact on HIV persistence (the “reservoir”) and health during antiretroviral therapy.

Dr. Deeks has published over 350 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants, and one of the principal investigators of DARE (the Delaney AIDS Research Enterprise), which is an NIH-funded international collaboratory aimed at developing therapeutic interventions to cure HIV infection. He a member of the Board of Directors for the UCSF-based amfAR Institute for HIV Cure Research. He is the co-chair of the “Towards an HIV Cure” International Working Group and a former co-chair of the NIH Office of AIDS Research Toward a Cure Planning Group. He is also a member of the Office of AIDS Research Advisory Council (ORAC). He was elected to the American Society for Clinical Investigation (ASCI), and serves on the advisory board for Science Translational Medicine and eBioMedicine. In addition to his clinical and translational investigation, Dr. Deeks maintains a primary care clinic for HIV infected patients, and was recently a member of the Department on Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents.

Competing Interests: Dr. Deeks is an advisor to InnaVirVax, Bionor Pharma and Bryologix and receives grant support from Gilead, Merck and ViiV.


Prof Sharon Lewin

Guest Editor, PLOS Medicine Advances in HIV Prevention, Treatment and Cure

Sharon Lewin is the inaugural director of the Peter Doherty Institute for Infection and Immunity, a joint venture between the University of Melbourne and Royal Melbourne Hospital; Professor of Medicine, The University of Melbourne; and consultant infectious diseases physician, Alfred Hospital, Melbourne, Australia. She is an infectious diseases physician and basic scientist.

Her research focuses on understanding why HIV persists on treatment and developing clinical trials aimed at ultimately finding a cure for HIV infection. In addition, she has had a long standing interest in understanding HIV-related immune reconstitution and the pathogenesis and management of common HIV co-infections, including hepatitis B virus. She is an elected member of the governing council of the International AIDS Society representing the Asia Pacific region and a member of the Strategic Technical Advisory Committee for the HIV and hepatitis program at the World Health Organization.

Competing Interests: Prof Lewin declares investigator initiated industry sponsored studies (payment to institution) from Merck, Gilead, Viiv Healthcare and Tetralogic. Advisory board and consultancy to Callimune, Tetralogic and InnaVirVax. Educational activities: Viiv, Gilead, BMS and Merck.